PRESSRELEASE

SHIONOGI

Shionogi to Showcase Advancements Across its Infectious Disease Portfolio at IDWeek 2026

Highlights Include an Oral Presentation of New Data from the Global Phase 3 SCORPIO-PEP Study and New Real-World Analysis on Respiratory Tract Infections from the PROVE Observational Study

---

Osaka, Japan, September 10, 2026 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi" or "the Company") today announced that it will present findings from across its broad anti-infective portfolio at IDWeek 2026 (October 21-24, 2026), in Washington, D.C., United States.

Data highlights at IDWeek 2026 include an oral presentation featuring a subpopulation analysis from the global Phase 3 SCORPIO-PEP trial, a rapid-fire session focused on ventilator-associated pneumonia isolates from the SENTRY Antimicrobial Surveillance Program and 18 additional presentations across Shionogi's COVID-19 antiviral and Gram-negative antibiotic programs.

"At IDWeek, we build on our legacy as a research-driven company by sharing new data from across our portfolio of marketed products and investigational therapies, while highlighting important milestones, including the FDA approval of XOCOVA and the acceptance of the supplemental New Drug Application for pediatric use of Fetroja," said Nathan McCutcheon, MBA, President and CEO, Shionogi Inc. "Equally important, IDWeek provides an opportunity to engage with the infectious disease community, deepen our understanding of evolving patient needs, and gain insights that help shape future research efforts and foster meaningful collaborations."

XOCOVA® (ensitrelvir) and COVID-19 data presentations:

- Oral Presentation October 23, 2026 3:15-3:27 PM: Early Pre-Symptomatic Treatment with Ensitrelvir Among PCR-Positive, SARS-CoV-2-Exposed and Infected Household Contacts: SCORPIO-PEP Subpopulation Analysis
- Poster #2100: Reduction of Infectious SARS-CoV-2 and Viral Titer with Ensitrelvir: A Pooled Analysis of SCORPIO-SR and SCORPIO-HR Trials
- Poster #2113: Impact of Acute COVID-19 on Underlying Chronic Conditions: Systematic Literature Review
- Poster #2149: Brain Microstructural Disorganization as a Potential Mechanism of post-COVID-19 Condition and the Onset-suppressive Effects of Ensitrelvir Revealed by Advanced Diffusion MRI–based Translational Research

- Poster #2143: Ensitrelvir Suppresses Fatigue-like Symptoms Derived from SARS-CoV-2 Infection in Hamsters

Fetroja® (cefiderocol) data presentations:

- Rapid Fire Session October 24, 2026 12:15-1:30 PM Poster #459: Cefiderocol Activity Across Highly Resistant *Pseudomonas aeruginosa* Ventilator-Associated Pneumonia Isolates: A Global Surveillance Study of SENTRY 2020-2024
- Poster #144: Outcomes of Cefiderocol Treatment in U.S. Patients with Respiratory Tract Infections: Subgroup Analysis of the PROVE Observational Study
- Poster #93: Clinical Outcomes After Cefiderocol Therapy for *Pseudomonas spp.* Infections: Results from a Systematic Literature Review
- Poster #94: Systematic Literature Review of the Clinical Outcomes Associated with Cefiderocol Therapy for *Stenotrophomonas maltophilia* Infections
- Poster #141: In vitro Activity of Cefiderocol (FDC) Against a Collection of Infrequently Isolated Gram-Negative Bacterial Isolates from the SENTRY Antimicrobial Surveillance Program
- Poster #1445: Activity of Cefiderocol Against Carbapenem-Resistant *Pseudomonas aeruginosa* Encountered in Each of the Different United States Census Bureau Divisions
- Poster #1465: Activity of cefiderocol against carbapenem-nonsusceptible Gram-negative isolates from skin and soft tissue infections in U.S. and European medical centers collected as part of the SENTRY antimicrobial surveillance program (2020-2024)
- Poster #160: Activity of Cefiderocol against Metallo-Beta-Lactamase Carrying *Pseudomonas aeruginosa* of the SENTRY Antimicrobial Surveillance Program (2020-2024)

Shionogi will also present preclinical research on xeruborbactam, an investigational beta-lactamase inhibitor, discovered by Qpex Biopharma, Inc., a Shionogi Group Company.

For full Prescribing Information for XOCOVA® (ensitrelvir), including approved indications and Safety Information, please visit https://www.shionogi.com/content/dam/shionogi/si/products/pdf/xocova.pdf

For full Prescribing Information for Fetroja® (cefiderocol), including approved indications and Safety Information, please visit https://www.shionogi.com/content/dam/shionogi/si/products/pdf/fetroja.pdf

About Shionogi Inc.

Shionogi Inc. is a U.S. subsidiary of Shionogi & Co., Ltd., a global research-driven pharmaceutical company. Since 1878, Shionogi has been developing new treatments to improve patients' lives worldwide. Today in North America, our portfolio of FDA-approved products includes an antibiotic for serious infections caused by susceptible Gram-negative bacteria, an oral antiviral for post-exposure prophylaxis of COVID-19 and a therapy for amyotrophic lateral sclerosis (ALS). Our pipeline programs include investigational treatments across infectious disease, rare disease and additional high-need

therapeutic areas. Together with our subsidiaries Qpex Biopharma Inc. and Shionogi Canada Inc., we are continuing to innovate for patients in the U.S. and worldwide. Learn more at shionogi.com.

About Shionogi in Infectious Disease

For more than 60 years, Shionogi has discovered and commercialized novel antibiotics. Today, our R&D story extends beyond antibiotics to include novel medications for HIV and influenza. Our global pipeline includes investigational agents to address global health challenges including antimicrobial resistance, COVID-19, influenza, rare fungal diseases and respiratory syncytial virus.

As part of our commitment to addressing unmet medical needs, Shionogi partners with several non-governmental organizations to increase equitable access to our medications worldwide. Shionogi and Global Antibiotic Research and Development Partnership (GARDP) have a license and technology transfer agreement and Shionogi and GARDP have a collaboration agreement with the Clinton Health Access Initiative (CHAI) that aim to transform the landscape of access to antibiotics in many low-income countries, most lower middle- and upper middle-income countries, and select high-income countries.

Shionogi ranked #2 among large research-based pharmaceutical companies in the Access to Medicine Foundation's 2026 Antimicrobial Resistance (AMR) Benchmark, a global assessment of how leading pharmaceutical companies are tackling antimicrobial resistance and expanding responsible access to antibiotics worldwide.

About Shionogi & Co., Ltd.

Shionogi & Co., Ltd. is a 148-year-old global, research-driven pharmaceutical company headquartered in Osaka, Japan, that is dedicated to bringing benefits to patients based on its corporate philosophy of "supplying the best possible medicine to protect the health and wellbeing of the patients we serve." The company currently markets products in several therapeutic areas including anti-infectives, pain, CNS disorders and cardiovascular diseases. Shionogi's research and development currently targets two therapeutic areas: infectious diseases and diseases with unmet medical needs in pain/CNS, including Alzheimer's disease, oncology, rare diseases, and sleep apnea. For more information on Shionogi & Co., Ltd., please visit https://www.shionogi.com/global/en.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and

foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information:

SHIONOGI Website Inquiry Form: https://www.shionogi.com/global/en/contact.html
U.S. Media: ShionogiCommunications@shionogi.com
Shionogi Europe Press Office: pressoffice@shionogi.eu